Matinas BioPharma Holdings, Inc. MTNB · Stock Open Matinas BioPharma Holdings, Inc. in new tab
Matinas BioPharma Holdings, Inc. Analysis (MTNB)
Is Matinas BioPharma Holdings, Inc. a good investment? Matinas BioPharma Holdings, Inc. (MTNB) is currently trading at 0.1739 USD.
Earnings Schedule: Matinas BioPharma Holdings, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -3.00.
Investor FAQ
Does Matinas BioPharma Holdings, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Matinas BioPharma Holdings, Inc.?
Matinas BioPharma Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.15.
Company Profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 3, 2024 | 1:50 |
Community Discussion